Two ways to get started with Sooma tDCS™

Non-invasive brain stimulation can be added to your practice in two ways. You can treat patients with your own Sooma tDCS devices, with full control over protocols and remote monitoring. Or, for patients who fall outside your clinic’s capacity, you can direct them to Sooma’s home therapy programme, which they purchase and run themselves.

Most clinics start with their own devices — it is the route that keeps the treatment inside your care pathway, where it can be individually adapted and tailored to the patient in front of you.

Book a demo

Option 1: Treat with your own Sooma tDCS devices

The full clinical toolset, under your control

You purchase Sooma tDCS devices for your clinic and use them across your patient population. The device is yours: it is a reusable asset, not a per-patient product. The device can be used with several patients by just exchanging the consumable parts (electrode pads). After the initial investment, the recurring cost of treating each additional patient is limited to consumables, which is what makes tDCS scalable as a routine service line rather than an occasional intervention.

What this route gives you:

• Remote monitoring through the Sooma Clinician Portal. Treatment logs, adherence data, dosage reports and patient-reported outcomes, whether the patient stimulates in your clinic or at home under your real-time supervision.
• Both indications, one platform. Depression and chronic pain protocols on the same device.
• Full parameter control. Session duration, intensity, number of sessions per day and total course length are set by you according to the patient-specific needs defined by your diagnosis, not by a fixed programme.
• Individualised protocols. Acute-phase intensity, tapering, maintenance schedules and re-treatment after relapse are all clinical decisions you make. Ready-made protocol templates are also available to streamline your workflow.
• Reimbursement pathways. In many markets, coding related to clinical and telemedicine visits may be applied for tDCS sessions
• A service you can price. Evaluation, treatment course and follow-up are billable clinical services, and the device supports a defined care package rather than a one-off product sale.
• Access to Sooma training and support. Our clinical team is available to train and support you every step of the way

Suited to: any setting where tDCS is being built into a standing care pathway, clinics treating patients in the acute phase, patients with complex histories or comorbidity, treatment-resistant cases, and patients who need protocol adjustment based on response.

Getting started: a demo and clinical walkthrough, onboarding and staff training, then your first patients. Onboarding is typically completed within weeks, and no specialist infrastructure is required.

Option 2: Refer patients to Sooma home therapy

Access for patients you cannot treat in clinic

Sooma tDCS™ Home Therapy is a standardised six-month treatment programme that the patient purchases directly from Sooma and runs at home, guided by the Sooma App. It is a separate product from the clinic device, with a fixed protocol and a fixed number of sessions. It is rather a treatment purchase than a device purchase.

This route exists because access is uneven. Some patients live too far from a treating unit, some services cannot offer continuation therapy after the acute phase, and some organisations are not equipped to run device-based therapies at all. Some clinics have long waiting lines and cannot immediately serve patients. For these patients, a standardised self-managed programme is meaningfully better than no treatment.

What the patient receives: a CE-certified device configured for the home programme, a structured six-month treatment plan, the guided app, and Sooma’s customer support. The purchase, delivery, billing and support relationship are between Sooma and the patient.

What it does not include: individualised protocol design, clinical follow-up, outcome monitoring, or remote oversight. The programme is fixed and self-managed. Remote monitoring of progress is not possible via a clinician dashboard but you may still be involved to provide the clinical value of a doctor’s involvement.

Suited to: patients who fit the standard protocol without adaptation, patients continuing after an acute course elsewhere, and patients who have no realistic access to device-based therapy through a treating unit.

How to refer: direct the patient to the Sooma webstore. There is no account, contract or administration required on your side, and no device logistics for your clinic to manage.

The hybrid model: start in clinic, continue at home

Where most long-term patients end up

For many patients, the barrier is not the acute course but everything after it. Attending a clinic daily for a few weeks is achievable. Sustaining maintenance stimulation for months, with the travel and appointment load that implies, often is not.

The hybrid model resolves this:

1. Acute phase in your clinic. You confirm suitability, deliver the intensive course on your own device at the intensity and frequency the patient’s presentation calls for, and assess response with your own protocol.
2. Transition. For responders who need to maintain the benefit but cannot keep attending, you discuss continuation of the standardised home programme, which the patient then purchases from Sooma.
3. Continued clinical contact, on your terms. You retain the therapeutic relationship. Periodic review appointments — remote or in person — to check symptom trajectory, treatment response and whether re-intensification is needed can be offered as a defined, billable follow-up service.

This keeps the clinically demanding phase where clinical judgement is required, and moves the logistically demanding phase to a format the patient can actually sustain. It also avoids the failure mode where a patient who responded well simply stops because continuation was impractical.

Clinics running higher volumes of maintenance patients often find the opposite conclusion is the right one: once a cohort of patients is on long-term continuation, keeping them on clinic devices under Portal monitoring gives better visibility and better economics. Our clinical team can work through the arithmetic for your specific patient flow.

At a glance

Which route fits your patients?

Choose your own devices if you expect to treat more than a handful of patients, want to build tDCS into a standing service, are treating acute or complex presentations, want to adjust protocols to response, or need outcome data.

Refer to home therapy if the patient fits the standard protocol as-is, needs long-term continuation rather than acute treatment, and has no practical route to clinician-delivered stimulation.

Combine both if your patients respond well in clinic but cannot sustain the visit burden long term.

The two are not alternatives to weigh against each other on price. They are different things: one is a clinical capability your service acquires, the other is a standardised treatment a patient buys. Clinician-led treatment remains the highest standard of care, and the recommended option wherever it is accessible.

Not sure which route fits your service?

Our clinical team works with over 300 hospitals and clinics and can walk through your patient pathway, volumes and setting with you.